Full Press Release Details
dupixent dupilumab approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis.
REGN
dupixent dupilumab approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Key Takeaway: dupixent dupilumab approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis